
|Articles|November 5, 2012
FDA expands use of rivaroxaban to treat, reduce recurrence of DVT, PE
FDA has expanded the approved use of oral anticoagulant rivaroxaban (Xarelto, Janssen) to include three new indications: treatment of deep vein thrombosis (DVT), treatment of pulmonary embolism (PE), and reducing the risk of recurrent DVT and PE following initial treatment.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
ACIP's Vacancy Leaves Pharmacists Navigating COVID-19 Confusion
2
COVID-19 in 2026: Why the Virus Still Threatens Vulnerable Patients
3
Study Links Live Flu Vaccine With Rise in Pneumococcal Disease
4
FDA-Approved Sunscreen Filter Bemotrizinol Debuts in New US Products
5





























